Targeting Glioblastoma Stem Cells: A40s Aptamer-NIR-Dye Conjugate for Glioblastoma Visualization and Treatment
Biomolecules · 2025
DOI: 10.3390/biom15060768 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Alessandra Affinito und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy. Hauptthemen laut MEDLINE: Glioblastoma, Aptamers, Nucleotide, Neoplastic Stem Cells, Brain Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PNRR-MUR NextGenerationEU, H2020-MSCA-RISE-2019, PNRR-MUR NextGenerationEU cod..
Abstract (Originalsprache)
Glioblastoma (GBM) is the most aggressive and challenging brain cancer, in terms of diagnosis and therapy. The highly infiltrative glioblastoma stem cells (GSCs) are difficult to visualize and surgically remove with the current diagnostic tools, which often lead to misdiagnosis and false-positive results. In this study, we focused on a groundbreaking tool for specifically visualizing and removing GSCs. We exploited the specific binding of A40s aptamer to EphA2 for the selective delivery of Near-Infrared Dyes (NIR-Dyes), like IR700DX and ICG, both in vitro and in vivo. The A40s aptamer, engineered through the NIR-Dye conjugation, did not affect aptamer binding ability; indeed, A40s-NIR-Dye conjugates bound GLI261 stem-like cells and patient-derived GSCs in vitro; moreover, they induced cell death upon photodynamic therapy treatment (PDT). Additionally, when systemically administrated, the A40s-NIR-Dye conjugates allowed GSC visualization and accumulated in tumor mass. This allows GSCs detection and treatment. Our findings demonstrate the potential use of A40s aptamer as a targeted therapeutic approach and imaging tool in vivo for GSCs, paving the way for improved, more effective, and less invasive GBM management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.
- AKA Biotech, 80131 Naples, Italy.
- Department of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133 Rome, Italy.
- Institute of Endotypes in Oncology, Metabolism and Immunology "Gaetano Salvatore" (IEOMI) CNR, 80131 Naples, Italy.
- Department of Molecular Genetics, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 CE Rotterdam, The Netherlands.
ORCID-Profile: Alessandra Affinito, Sara Verde, Aurelia Fraticelli, Martina Mascolo, Gianluca Petrillo, Laura Mezzanotte
Förderung
- PNRR-MUR NextGenerationEU
- H2020-MSCA-RISE-2019
- PNRR-MUR NextGenerationEU cod.
Zitieren
APA
Affinito, A., Ingenito, F., Verde, S., Musella, E., Pattanayak, B., Fiore, D., Quintavalle, C., Fraticelli, A., Mascolo, M., Petrillo, G., Pignataro, C., De Luca, G., Mezzanotte, L., & Condorelli, G. (2025). Targeting Glioblastoma Stem Cells: A40s Aptamer-NIR-Dye Conjugate for Glioblastoma Visualization and Treatment. Biomolecules. https://doi.org/10.3390/biom15060768
Vancouver
Affinito A, Ingenito F, Verde S, Musella E, Pattanayak B, Fiore D, et al. Targeting Glioblastoma Stem Cells: A40s Aptamer-NIR-Dye Conjugate for Glioblastoma Visualization and Treatment. Biomolecules. 2025. doi:10.3390/biom15060768
BibTeX
@article{Affinito2025,
author = {Affinito, Alessandra and Ingenito, Francesco and Verde, Sara and Musella, Emanuele and Pattanayak, Birlipta and Fiore, Danilo and Quintavalle, Cristina and Fraticelli, Aurelia and Mascolo, Martina and Petrillo, Gianluca and Pignataro, Claudia and De Luca, Giada and Mezzanotte, Laura and Condorelli, Gerolama},
title = {Targeting Glioblastoma Stem Cells: A40s Aptamer-NIR-Dye Conjugate for Glioblastoma Visualization and Treatment},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15060768}
}
EUVIMED